New hope for kids with kidney disease: finerenone trial launches
NCT ID NCT07315191
First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 18 times
Summary
This study tests finerenone, a drug that may reduce kidney inflammation and protein leakage, in children aged 3–17 with Henoch-Schönlein purpura nephritis and mild proteinuria. About 116 participants will receive finerenone to see if it lowers urine protein better than current standard care. The goal is to prevent long-term kidney damage without needing lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HENOCH SCHÖNLEIN PURPURA NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Capital Center for Children's Health,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.